SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the Company will present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9 at 10:25 a.m. ET in New York, NY.
News
Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707
SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, announced today it has opened HAMMER, a global, Phase 1/2, first… […]
News
Synthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the presentation of three ?posters at the upcomi… […]
News
Synthorx Reports Third Quarter Financial Results
SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today reported financial results and provided a business update … […]
